PubRank

Joanne M Bowen

Author PubWeight™ 34.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 2007 2.24
2 The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007 1.47
3 Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2007 1.35
4 Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2012 1.27
5 Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2008 1.12
6 Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 2009 1.07
7 Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 2008 1.06
8 Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008 1.05
9 Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003 1.05
10 Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 2010 1.05
11 Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005 1.01
12 Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol 2008 1.00
13 Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013 0.99
14 Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013 0.97
15 A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther 2007 0.96
16 Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract 2012 0.95
17 Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009 0.93
18 Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013 0.93
19 Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 2008 0.93
20 Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 2005 0.92
21 Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol 2012 0.91
22 Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 2009 0.91
23 Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 2007 0.89
24 Biomarkers of regimen-related mucosal injury. Cancer Treat Rev 2011 0.87
25 Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) 2010 0.85
26 Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol 2009 0.85
27 Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 2007 0.85
28 Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Curr Opin Support Palliat Care 2013 0.84
29 Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma. J Gastrointest Surg 2015 0.84
30 Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther 2007 0.80
31 Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs 2008 0.80
32 Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Support Care Cancer 2014 0.79
33 Technological advances in mucositis research: new insights and new issues. Cancer Treat Rev 2008 0.78
34 New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opin Biol Ther 2014 0.77
35 Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy 2011 0.77
36 Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. J Support Oncol 2013 0.76
37 Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. Int J Exp Pathol 2011 0.76
38 Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Support Palliat Care 2016 0.76
39 TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity? Int J Cancer 2014 0.76
40 Editorial Comment: Does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner? Curr Opin Support Palliat Care 2015 0.75